The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01.
P R Graves; L Yu; J K Schwarz; J Gales; E A Sausville; P M O'Connor; H Piwnica-Worms (Profiled Author: Edward A Sausville)
Department of Cell Biology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
The Journal of biological chemistry 2000;275(8):5600-5.
A checkpoint operating in the G(2) phase of the cell cycle prevents entry into mitosis in the presence of DNA damage. UCN-01, a protein kinase inhibitor currently undergoing clinical trials for cancer treatment, abrogates G(2) checkpoint function and sensitizes p53-defective cancer cells to DNA-damaging agents. In most species, the G(2) checkpoint prevents the Cdc25 phosphatase from removing inhibitory phosphate groups from the mitosis-promoting kinase Cdc2. This is accomplished by maintaining Cdc25 in a phosphorylated form that binds 14-3-3 proteins. The checkpoint kinases, Chk1 and Cds1, are proposed to regulate the interactions between human Cdc25C and 14-3-3 proteins by phosphorylating Cdc25C on serine 216. 14-3-3 proteins, in turn, function to keep Cdc25C out of the nucleus. Here we report that UCN-01 caused loss of both serine 216 phosphorylation and 14-3-3 binding to Cdc25C in DNA-damaged cells. In addition, UCN-01 potently inhibited the ability of Chk1 to phosphorylate Cdc25C in vitro. In contrast, Cds1 was refractory to inhibition by UCN-01 in vitro, and Cds1 was still phosphorylated in irradiated cells treated with UCN-01. Thus, neither Cds1 nor kinases upstream of Cds1, such as ataxia telangiectasia-mutated, are targets of UCN-01 action in vivo. Taken together our results identify the Chk1 kinase and the Cdc25C pathway as potential targets of G(2) checkpoint abrogation by UCN-01.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
L Yu; L Orlandi; P Wang; M S Orr; A M Senderowicz; E A Sausville; R Silvestrini; N Watanabe; H Piwnica-Worms; P M O'ConnorThe Journal of biological chemistry 1998;273(50):33455-64.
Surabhi Dangi; Hyukjin Cha; Paul ShapiroCellular signalling 2003;15(7):667-75.
G B Carey; J P LibertiArchives of biochemistry and biophysics 1995;316(1):179-89.
Appears in this Publication
Author of this Publication